Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptimmune Therapeutics plc (ADAP) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as an issuer with American Depositary Shares previously listed on The Nasdaq Capital Market. These filings include current reports on Form 8-K, annual and quarterly reports referenced in company communications, and other documents that outline Adaptimmune’s financial condition, strategic transactions and corporate governance developments.
Through its Form 8-K filings, Adaptimmune reports material events such as notices from Nasdaq regarding minimum bid price deficiencies and the Low Priced Stocks Rule, approval to transfer its listing to the Nasdaq Capital Market, and the Board’s decision to voluntarily delist its ADSs and deregister them under Section 12(b) of the Securities Exchange Act of 1934. Filings also describe the company’s intention to file a Form 25 to effect the delisting and a subsequent Form 15 to suspend its reporting obligations once eligibility criteria are met.
Other key SEC documents detail the Asset Purchase Agreement and related transaction by which Adaptimmune sold the assets and rights related to its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC. These filings outline the upfront cash consideration, potential milestone payments, assumed liabilities, and associated license and transition services agreements, as well as the use of proceeds to repay indebtedness under a Loan and Security Agreement with Hercules Capital, Inc.
Adaptimmune’s 8-K filings also cover restructuring actions and workforce reductions, executive leadership changes, and separation or consulting agreements with senior officers, providing detail on severance terms and responsibilities. Financial information referenced in these filings, including revenue, research and development expenses, selling, general and administrative expenses, net income or loss, and the non-GAAP Total Liquidity measure, can be compared with press release summaries for a fuller picture of the company’s performance.
Stock Titan enhances these SEC filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand listing status changes, asset sales, restructuring plans and liquidity disclosures. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while structured views make it easier to follow Adaptimmune’s transition from a Nasdaq-listed cell therapy company with commercial assets to an issuer focused on remaining preclinical programs and strategic alternatives.
EcoR1 Capital, LLC, a 10% owner of Adaptimmune Therapeutics plc (ADAP), filed a Form 4 disclosing three consecutive open-market sales of American Depositary Shares (ADSs) between 28-30 Jul 2025.
- 28 Jul 2025: sold 5,655,290 ADSs (33,931,740 ordinary shares) at a $0.1125 weighted-average price.
- 29 Jul 2025: sold 447,910 ADSs (2,687,460 shares) at $0.1012.
- 30 Jul 2025: sold 4,572,223 ADSs (27,433,338 shares) at $0.1021.
The aggregate disposal totals 10,675,423 ADSs, equivalent to 64,052,538 ordinary shares. Post-transaction, EcoR1’s beneficial ownership stands at 16,728,647 ADSs (100,371,882 ordinary shares) held indirectly through its funds.
No derivative transactions were reported. The filing signals a sizable reduction in EcoR1’s stake, though the firm remains an insider owning more than 10% of ADAP’s equity.
Adaptimmune Therapeutics (ADAP) has agreed to sell its four autologous T-cell therapy programs—TECELRA, lete-cel, afami-cel and uza-cel—to US WorldMeds for $55 million cash at closing plus up to $30 million in regulatory and commercial milestones.
Proceeds will immediately repay the company’s outstanding Hercules Capital loan. US WorldMeds will assume selected liabilities, acquire manufacturing assets, licences and regulatory files, and offer jobs to roughly half of Adaptimmune’s staff. Adaptimmune will provide transition services through 30 June 2026.
Restructuring: Following the deal, Adaptimmune plans to cut its remaining workforce by ≈62 %, booking $7–8 million in severance costs (mainly Q3-25). Senior leaders—including the Chief Medical, Commercial, Scientific and Financial Officers—will depart in August 2025.
The transaction must close by 4 Aug 2025, subject to customary conditions and the absence of any material adverse effect.
- $5 M on FDA BLA acceptance for lete-cel
- $10 M on FDA approval for lete-cel
- Up to $5 M if TECELRA quarterly U.S. sales ≥$18 M
- $10 M if combined U.S. sales of TECELRA & lete-cel ≥$200 M